ARS Pharmaceuticals narrows Q3 net loss to $35.6M
neffy’s U.S. market share reached 5%, while ARS continues to expect cash flow breakeven by the end of 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ARS Pharmaceuticals, Inc. reported third-quarter 2026 revenue of $37.7 million, including $33.4 million in U.S. neffy net product revenue, $2.6 million in supply revenue and $1.7 million in collaboration revenue, versus $32.5 million a year earlier. U.S. neffy market share was 5%, up from 4%, and approximately 9% in field-targeted accounts, versus 6%; those accounts represent approximately 44% of the total market opportunity.
Operating expenses were $71.9 million. Aggregate SG&A and R&D spending is tracking in line with second-half 2026 guidance of $114 million to $126 million, including stock-based compensation. SG&A was $43.5 million versus $74.8 million in Q3 2025; R&D was $18.3 million, including a one-time $12.5 million payment under a license agreement. Net loss was $35.6 million, or $(0.36) per share, versus $51.2 million, or $(0.52) per share. Cash, cash equivalents and short-term investments totaled $138.4 million as of September 30, 2026; ARS continues to expect cash flow breakeven by the end of 2027. ARS-2 is in a Phase 2b trial for breakthrough flares of chronic spontaneous urticaria, with interim data expected in the first quarter of 2027 and full data later in 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQ3 revenue: $37.7 million, versus $32.5 million in Q3 2025.
- Moderate pointQ3 net loss narrowed to $35.6 million from $51.2 million in Q3 2025.
Negative
- None.
Filing Explained
At September 30, ARS reported $121,807 thousand in net term loans and a $75,208 thousand financing liability.
The 8-K furnishes third-quarter results; its September 30 balance sheet reports
The balance sheet lists ARS Pharmaceuticals common shares issued and outstanding as 100,248,400 at September 30, 2026, and 99,290,926 at December 31, 2025.
8-K Event Classification
Key Figures
Key Terms
net product revenue financial
stock-based compensation financial
cash flow breakeven financial
chronic spontaneous urticaria (CSU) medical
Phase 2b medical
Earnings Snapshot
Aggregate SG&A and R&D spending is tracking in line with second-half 2026 guidance of $114 million to $126 million, including stock-based compensation. The company continues to expect cash flow breakeven by the end of 2027 based on its current expense base plan.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did SPRY report in Q3 2026?
How many prescribers did neffy have in Q3 2026?
When does ARS expect interim ARS-2 trial data?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit Number |
|
Description |
99.1 |
|
Press Release dated November 5, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ARS PHARMACEUTICALS, INC. |
|
|
|
|
|
Date: November 5, 2026 |
|
By: |
/s/ Donn Casale |
|
|
|
Donn Casale |
|
|
|
President and Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
Exhibit 99.1
ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy®
neffy U.S. market share reached 5% overall and 9% in field-targeted accounts, supporting the company’s updated targeted provider commercial strategy
Reduced SG&A spend reflected in Q3 operating expenses; reaffirm path to cash flow breakeven by year-end 2027
Leadership team strengthened with appointments of Randall Kaye, M.D., as Chief Medical Officer and John Slebir as Chief Legal Officer
Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT
SAN DIEGO, Nov. 5, 2026 -- ARS Pharmaceuticals (Nasdaq: SPRY), a commercial biopharmaceutical company focused on needle-free epinephrine, today reported its financial results for the third quarter ended September 30, 2026, as well as recent corporate and commercial highlights.
“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each,” said Donn Casale, President and Chief Executive Officer of ARS Pharma. “Market share grew where our field team engaged; operating expenses were in line with guidance, including a 42% reduction in third-quarter SG&A expenses from the first-half 2026 quarterly average; and ARS-2 is on track for interim Phase 2b data in the first quarter of 2027.
“These results build the foundation for our future-looking three-pillar growth strategy – capture market share with neffy in our base market; expand the epinephrine market over time; and extend our platform, starting with our chronic spontaneous urticaria. With new leadership in place across our commercial, medical and legal functions, we have the team, the strategy and the discipline to execute. The opportunity in front of us is significant, and we believe we are well positioned to pursue it with focus and urgency.”
Third Quarter 2026 neffy Commercial Highlights
“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market,” said Meg Smith, Chief Commercial Officer. “The data show that when we engage providers directly, neffy wins. In my first two months, we completed a comprehensive assessment of our commercial operations, and we are taking decisive action across multiple fronts, including implementing a shift to account-based targeting, sharper provider-focused messaging, and a strengthened market access strategy. We are moving with urgency, and I expect the progress will continue to be reflected in our results, with steady gains over time.”
Business Updates
Leadership Appointments
ARS further strengthened its leadership team to execute its updated corporate and commercial strategy. In addition to the appointment of Meg Smith as Chief Commercial Officer in August 2026, the company also appointed:
Pipeline Expansion
ARS-2 is progressing in a Phase 2b trial evaluating 0.5 mg and 1.0 mg doses of needle-free epinephrine for the on-demand treatment of breakthrough flares in patients with chronic spontaneous urticaria (CSU). An estimated two million Americans live with CSU, and no FDA-approved therapy is indicated to stop an acute flare in progress. Interim data from the Phase 2b trial are expected in the first quarter of 2027, with full data later in 2027, which will inform the design of a potential Phase 3 registration program.
Third Quarter 2026 Financial Results
Conference Call and Webcast
ARS will host a conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast will be available in the Investors & Media section of www.ars-pharma.com. Participants may register for dial-in access through the same page. A replay will be available for 30 days.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company developing and commercializing treatments that help at-risk patients and their caregivers treat and prevent severe allergic reactions. The company is commercializing neffy® (epinephrine nasal spray), the only needle-free epinephrine approved by the U.S. Food & Drug Administration, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15 kg) or more. In the European Union, the product is marketed as EURneffy®, the only needle-free epinephrine product authorized by the European Commission, for the emergency treatment of allergic reactions, including anaphylaxis, in adults and children four years of age and older weighing 15 kg or more. The product is also marketed as 优敏速® in China. Leveraging its intranasal technology, ARS Pharma is also developing ARS-2, currently in a Phase 2b clinical trial, as a potential first treatment for acute breakthrough flares of chronic spontaneous urticaria (CSU). For more information, visit www.ars-pharma.com and follow us on LinkedIn.
Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: ARS Pharma’s updated strategic priorities and the anticipated benefits of their implementation, including a reduction in projected SG&A and R&D expenses for the second half of 2026 and expectations regarding operating expense trends into 2027; the anticipated path and timing to cash flow breakeven; the expected impact of the appointments of a new Chief Commercial Officer, Chief Medical Officer and Chief Legal Officer; the belief that neffy could become a standard of care; the expectation that the company’s shift to account-based targeting, provider-focused messaging and strengthened market access strategy will continue to be reflected in its results through steady gains over time; the anticipated timing for interim data from the urticaria trial and the potential for ARS Pharma’s intranasal epinephrine technology to expand into the urticaria indication; the expectation that realigning commercial investment toward targeted provider engagement will expand market share and support a durable growth trajectory for neffy; the potential for the CSU program to leverage existing commercial infrastructure and overlapping targeted prescribers and to represent a high-margin growth driver, if approved; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “believe,” “can,” “expect,” “if,” “intend,” “may,” “on track,” “potential,” “plan,” “will,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; the ability to maintain regulatory approval for neffy in its currently approved indications; the scope, progress and expansion of developing and commercializing neffy; the risk that personnel costs will be higher than anticipated; the scope, progress and expansion of developing our intranasal epinephrine technology; clinical trial results; the potential for governments and payors to delay, limit or deny coverage for neffy; the size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharma’s ability to protect its intellectual property position; the adverse effects of pending litigation; and the impact of government laws, regulations and policies. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption 'Risk Factors' in ARS Pharma's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and as updated by the 'Risk Factors' in ARS Pharma's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. These documents are filed with the Securities and Exchange Commission and can also be accessed on ARS Pharma’s website at www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab. The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Contacts
Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
ARS Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except par value and share amounts)
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
25,621 |
|
|
$ |
41,317 |
|
Short-term investments |
|
|
112,733 |
|
|
|
203,669 |
|
Accounts receivable, net |
|
|
52,757 |
|
|
|
25,347 |
|
Inventories |
|
|
11,711 |
|
|
|
8,369 |
|
Prepaid expenses and other current assets |
|
|
8,206 |
|
|
|
6,194 |
|
Total current assets |
|
|
211,028 |
|
|
|
284,896 |
|
Inventories, noncurrent |
|
|
21,720 |
|
|
|
23,053 |
|
Property, plant and equipment, net |
|
|
1,927 |
|
|
|
2,465 |
|
Intangible assets, net |
|
|
13,624 |
|
|
|
14,452 |
|
Other assets |
|
|
3,185 |
|
|
|
2,786 |
|
Total assets |
|
$ |
251,484 |
|
|
$ |
327,652 |
|
Liabilities and stockholders’ (deficit) equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable and accrued liabilities (including related party amounts of $2,436 and $1,624, respectively) |
|
$ |
63,793 |
|
|
$ |
37,948 |
|
Contract liability, current |
|
|
511 |
|
|
|
609 |
|
Other current liabilities |
|
|
599 |
|
|
|
588 |
|
Total current liabilities |
|
|
64,903 |
|
|
|
39,145 |
|
Term loans, net (including related party amounts of $4,842 and $4,819, respectively) |
|
|
121,807 |
|
|
|
96,374 |
|
Financing liability |
|
|
75,208 |
|
|
|
72,140 |
|
Contract liability, net of current portion |
|
|
1,047 |
|
|
|
1,130 |
|
Other accrued liabilities |
|
|
474 |
|
|
|
4,605 |
|
Total liabilities |
|
|
263,439 |
|
|
|
213,394 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ (deficit) equity |
|
|
|
|
|
|
||
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value per share; 200,000,000 shares authorized at September 30, 2026 and December 31, 2025; 100,248,400 and 99,290,926 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively |
|
|
10 |
|
|
|
10 |
|
Additional paid-in capital |
|
|
441,286 |
|
|
|
408,726 |
|
Accumulated other comprehensive (loss) gain, net |
|
|
(104 |
) |
|
|
125 |
|
Accumulated deficit |
|
|
(453,147 |
) |
|
|
(294,603 |
) |
Total stockholders’ (deficit) equity |
|
|
(11,955 |
) |
|
|
114,258 |
|
Total liabilities and stockholders’ (deficit) equity |
|
$ |
251,484 |
|
|
$ |
327,652 |
|
ARS Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue, net |
|
$ |
33,414 |
|
|
$ |
31,300 |
|
|
$ |
77,076 |
|
|
$ |
51,863 |
|
Revenue under collaboration agreements |
|
|
1,661 |
|
|
|
55 |
|
|
|
4,207 |
|
|
|
2,859 |
|
Revenue under supply agreements |
|
|
2,635 |
|
|
|
1,146 |
|
|
|
12,766 |
|
|
|
1,469 |
|
Total revenue |
|
|
37,710 |
|
|
|
32,501 |
|
|
|
94,049 |
|
|
|
56,191 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of goods sold (including related party amounts of $1,711, $2,046, $4,795, and $3,400, respectively) |
|
|
10,098 |
|
|
|
8,191 |
|
|
|
29,230 |
|
|
|
14,269 |
|
Research and development (including related party amounts of $551, $559, $1,830, and $1,804, respectively) |
|
|
18,263 |
|
|
|
2,751 |
|
|
|
27,297 |
|
|
|
9,738 |
|
Selling, general and administrative (including related party amounts of $101, $123, $362, and $354, respectively) |
|
|
43,520 |
|
|
|
74,751 |
|
|
|
193,303 |
|
|
|
170,167 |
|
Total operating expenses |
|
|
71,881 |
|
|
|
85,693 |
|
|
|
249,830 |
|
|
|
194,174 |
|
Loss from operations |
|
|
(34,171 |
) |
|
|
(53,192 |
) |
|
|
(155,781 |
) |
|
|
(137,983 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
1,136 |
|
|
|
2,097 |
|
|
|
4,709 |
|
|
|
8,065 |
|
Interest expense (including related party amounts of $127, $3, $373, and $3, respectively) |
|
|
(2,552 |
) |
|
|
(56 |
) |
|
|
(7,472 |
) |
|
|
(56 |
) |
Total other (expense) income, net |
|
|
(1,416 |
) |
|
|
2,041 |
|
|
|
(2,763 |
) |
|
|
8,009 |
|
Net loss |
|
$ |
(35,587 |
) |
|
$ |
(51,151 |
) |
|
|
(158,544 |
) |
|
|
(129,974 |
) |
Unrealized gains (losses) on available-for-sale securities |
|
|
36 |
|
|
|
39 |
|
|
|
(229 |
) |
|
|
(227 |
) |
Comprehensive loss |
|
$ |
(35,551 |
) |
|
$ |
(51,112 |
) |
|
$ |
(158,773 |
) |
|
$ |
(130,201 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.36 |
) |
|
$ |
(0.52 |
) |
|
$ |
(1.59 |
) |
|
$ |
(1.32 |
) |
Weighted-average shares outstanding used in computing net loss per share, basic and diluted |
|
|
99,685,424 |
|
|
|
98,807,600 |
|
|
|
99,432,878 |
|
|
|
98,412,739 |
|